The global tuberculosis medicine researches and develops the alliance and tests the new medicinal treatment
It is reported the global tuberculosis medicine researches and develops the alliance (TBAlliance) Announce on November 11, will launch the first clinical trial, the new tuberculosis medicinal treatment taking testing a name as NC001, such new treatment formed after three kinds of medicines are made up, will be used mainly for treating the sensitive pulmonary tuberculosis (DS-TB) of medicine With able to bear pulmonary tuberculosis of many medicines (MDR-TB)ing ,And expected to shorten and simplify the course of treatment of pulmonary tuberculosis by a wide margin in the world, will treat time to shorten from 2 to less than 6 months. "Dispel pulmonary tuberculosis, what we need is not merely a new medicine, but is a kind of brand-new healing solution, there is group of the second largest pulmonary tuberculosis patient in the whole world in China, new treatment will bring good news for the Chinese patient. " The global tuberculosis medicine is developed Dr. Ma ZhenKun, chief scientist of alliance, and said.
It is with 2 million people died that pulmonary tuberculosis is caused in the whole world every year, because the long, method of course of treatment to treat pulmonary tuberculosis at present is complicated, a lot of patients can't finish treating, so that this disease one is able to bear nature to strengthen constantly, become a severe global health threat day by day. Annual the whole world appear over 500,000 able to bear the pulmonary tuberculosis case of nature newly. NC001 clinical trial carries on two centres in South Africa, has 68 patients' participation together, each person accepts drug therapy and 3 months -long follow-up of two weeks are observed, in order to test the validity, security and drug resistance of the new treatment. (sharp point Pan Zhao right)
The global tuberculosis medicine researches and develops the alliance and tests the new medicinal treatment
No comments:
Post a Comment